About Cannabis Science (OTCMKTS:CBIS)
Cannabis Science, Inc. is engaged in medical marijuana research and development. The Company works on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. The Company is involved in the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. The Company focuses on the development of governmentally approved pharmaceuticals, including CS-TATI1, CS-S/BCC-1 and neurological therapy under study or development. The Company's subsidiaries include Cannabis Science BV and Cannabis Science International Holding BV.
Industry, Sector and Symbol:
Capitalization:- Market Cap: $75.91 million
- Outstanding Shares: 2,521,805,000
Average Prices:- 50 Day Moving Avg: $0.04
- 200 Day Moving Avg: $0.05
- 52 Week Range: $0.02 - $0.14
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: 0.0000
Sales & Book Value:- Annual Revenue: $7,461.00
- Price / Sales: 10,173.75
- Book Value: $0.00 per share
- Price / Book: -30.10
Profitability:- EBITDA: ($9,040,000.00)
- Net Margins: -953,196.00%
- Return on Assets: -380.46%
Misc:- Average Volume: 7.39 million shs.
Frequently Asked Questions for Cannabis Science (OTCMKTS:CBIS)
What is Cannabis Science's stock symbol?
Cannabis Science trades on the OTCMKTS under the ticker symbol "CBIS."
How were Cannabis Science's earnings last quarter?
Cannabis Science Inc (OTCMKTS:CBIS) released its quarterly earnings data on Tuesday, July, 28th. The company reported $0.00 earnings per share for the quarter. View Cannabis Science's Earnings History.
Who are some of Cannabis Science's key competitors?
Some companies that are related to Cannabis Science include Palatin Technologies (PTN), Sinclair Pharma PLC (SPH), Asterias Biotherapeutics (AST), Asterias Biotherapeutics (AST), Verona Pharma Plc (VRP), ImmuPharma PLC (IMM), Harvard Bioscience (HBIO), MaxCyte (MXCT), Bovie Medical (BVX), Arch Therapeutics (ARTH), Ekf Diagnostics Holding PLC (EKF), Synthetic Biologics (SYN), Matinas BioPharma Holdings (MTNB), Summit Therapeutics PLC (SUMM), Nobilis Health Corp (HLTH), Motif Bio PLC (MTFB), Immunodiagnostic Systems Holdings PLC (IDH) and Ergomed PLC (ERGO).
Who are Cannabis Science's key executives?
Cannabis Science's management team includes the folowing people:
- Raymond C. Dabney, President, Chief Executive Officer, Director
- Benjamin C.K. Tam, Chief Financial Officer, Secretary, Director
- Robert Kane, Chief Operating Officer, Director
- Mario Lap, Director
How do I buy Cannabis Science stock?
Shares of Cannabis Science can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cannabis Science's stock price today?
One share of Cannabis Science stock can currently be purchased for approximately $0.03.
MarketBeat Community Rating for Cannabis Science (OTCMKTS CBIS)MarketBeat's community ratings are surveys of what our community members think about Cannabis Science and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Cannabis Science (OTCMKTS:CBIS) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Consensus Price Target History for Cannabis Science (OTCMKTS:CBIS)
Analysts' Ratings History for Cannabis Science (OTCMKTS:CBIS)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Cannabis Science (OTCMKTS:CBIS)Earnings History by Quarter for Cannabis Science (OTCMKTS CBIS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 7/28/2015 | Q3 2016 | | $0.00 | | | View | N/A |  |
(Data available from 1/1/2011 forward)
Earnings Estimates for Cannabis Science (OTCMKTS:CBIS)No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Cannabis Science (OTCMKTS:CBIS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Cannabis Science (OTCMKTS:CBIS)Insider Trades by Quarter for Cannabis Science (OTCMKTS:CBIS)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 10/20/2016 | Robert James Kane | COO | Sell | 2,000,000 | $0.07 | $140,000.00 | |
| 10/19/2016 | Robert James Kane | COO | Sell | 4,000,000 | $0.04 | $160,000.00 | |
| 10/14/2016 | Robert James Kane | CFO | Sell | 1,389,577 | $0.02 | $27,791.54 | |
| 10/10/2016 | Robert James Kane | CFO | Sell | 1,783,475 | $0.02 | $35,669.50 | |
| 9/13/2016 | Robert James Kane | CFO | Sell | 2,000,000 | $0.01 | $20,000.00 | |
| 5/18/2016 | Robert James Kane | CFO | Sell | 503,345 | $0.02 | $10,066.90 | |
| 5/6/2016 | Robert James Kane | CFO | Sell | 300,000 | $0.02 | $6,000.00 | |
| 3/31/2016 | Chad Steven Johnson | COO | Sell | 500,000 | $0.02 | $10,000.00 | |
| 3/29/2016 | Chad Steven Johnson | COO | Sell | 2,402,000 | $0.02 | $48,040.00 | |
| 3/21/2016 | Chad Steven Johnson | COO | Sell | 483,852 | $0.02 | $9,677.04 | |
| 3/3/2016 | Chad Steven Johnson | COO | Sell | 2,188,334 | $0.01 | $21,883.34 | |
| 2/29/2016 | Chad Steven Johnson | COO | Sell | 4,370,000 | $0.01 | $43,700.00 | |
| 2/19/2016 | Chad Steven Johnson | COO | Sell | 1,765,300 | $0.01 | $17,653.00 | |
| 12/11/2015 | Chad Steven Johnson | COO | Sell | 1,646,142 | $0.02 | $32,922.84 | |
| 12/3/2015 | Chad Steven Johnson | COO | Sell | 769,986 | $0.02 | $15,399.72 | |
| 12/2/2015 | Chad Steven Johnson | COO | Sell | 1,852,239 | $0.02 | $37,044.78 | |
| 8/19/2015 | Chad Steven Johnson | COO | Sell | 6,500,000 | $0.03 | $195,000.00 | |
| 6/9/2015 | Chad Steven Johnson | COO | Sell | 1,063,575 | $0.03 | $31,907.25 | |
| 4/29/2015 | Chad Steven Johnson | COO | Sell | 921,333 | $0.04 | $36,853.32 | |
| 3/27/2015 | Chad Steven Johnson | COO | Sell | 1,400,000 | $0.04 | $56,000.00 | |
| 3/19/2015 | Chad Steven Johnson | COO | Sell | 1,262,691 | $0.05 | $63,134.55 | |
| 2/4/2015 | Chad Steven Johnson | COO | Sell | 1,809,914 | $0.06 | $108,594.84 | |
| 1/20/2015 | Chad Steven Johnson | COO | Sell | 255,000 | $0.07 | $17,850.00 | |
| 1/14/2015 | Dh Bray | CEO | Sell | 1,260,750 | $0.06 | $75,645.00 | |
| 1/5/2015 | Chad Steven Johnson | COO | Sell | 1,600,000 | $0.07 | $112,000.00 | |
| 11/20/2014 | Chad Steven Johnson | COO | Sell | 433,990 | $0.07 | $30,379.30 | |
| 11/14/2014 | Chad Steven Johnson | COO | Sell | 251,110 | $0.06 | $15,066.60 | |
| 11/3/2014 | Chad Steven Johnson | COO | Sell | 400,000 | $0.09 | $36,000.00 | |
| 10/31/2014 | Chad Steven Johnson | COO | Sell | 750,000 | $0.08 | $60,000.00 | |
| 2/13/2014 | Robert Melamede | Major Shareholder | Sell | 425,800 | $0.17 | $72,386.00 | |
| 2/11/2014 | Robert Melamede | Major Shareholder | Sell | 779,200 | $0.19 | $148,048.00 | |
| 2/6/2014 | Robert Melamede | Major Shareholder | Sell | 473,300 | $0.25 | $118,325.00 | |
| 2/4/2014 | Robert Melamede | Major Shareholder | Sell | 659,700 | $0.19 | $125,343.00 | |
| 1/30/2014 | Robert Melamede | Major Shareholder | Sell | 600,200 | $0.19 | $114,038.00 | |
| 1/27/2014 | Robert Melamede | Major Shareholder | Sell | 525,000 | $0.14 | $73,500.00 | |
| 1/22/2014 | Robert Melamede | Major Shareholder | Sell | 476,500 | $0.11 | $52,415.00 | |
| 1/16/2014 | Robert Melamede | Major Shareholder | Sell | 425,800 | $0.10 | $42,580.00 | |
| 1/13/2014 | Robert Melamede | Major Shareholder | Sell | 248,800 | $0.12 | $29,856.00 | |
| 1/9/2014 | Robert Melamede | Major Shareholder | Sell | 170,200 | $0.13 | $22,126.00 | |
| 1/7/2014 | Robert Melamede | Major Shareholder | Sell | 132,200 | $0.07 | $9,254.00 | |
| 1/3/2014 | Robert Melamede | Major Shareholder | Sell | 83,300 | $0.07 | $5,831.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Cannabis Science (OTCMKTS:CBIS)
Latest Headlines for Cannabis Science (OTCMKTS:CBIS)
| Source: |
|
| Date | Headline |
|---|
 | Mounting Evidence on Therapeutic Benefits of Cannabis Unleashes Tsunami - PR Newswire (press release)
www.prnewswire.com - October 18 at 11:18 PM |
 | CBIS/FSO NAC Makes Headway with American States University 250-Acre Industrial Hemp Project with Major Purchase Interests from Ministry of Health, Medical Practitioners, and Other Significant Groups Representing Vast Community Economic Growth
finance.yahoo.com - October 5 at 11:49 AM |
| Legal and Medical Cannabis Market Expected to Show Strong Growth - PR Newswire (press release)
www.prnewswire.com - September 26 at 4:00 PM |
| Cannabis Science "Nanoparticle Drones to Target Lung Cancer with Radiosensitizers and Cannabinoids" Full Publication Released Today In Frontiers In Oncology
finance.yahoo.com - September 19 at 5:01 PM |
| Cannabis Science Announces Publication of Initial Research Results Using Nanoparticle Drones to Target Lung Cancer With Radiosensitizers and Cannabinoids in the Renowned Journal Frontiers in Oncology
finance.yahoo.com - September 14 at 5:46 PM |
| Cannabis Science Announces Participation in Major U.S.-Africa Policy Forum in Washington, DC
finance.yahoo.com - September 11 at 5:35 PM |
 | Cannabis Science and Free Spirit Organics Native American Corporation Report Positive Analytical Lab Results From ... - Benzinga
www.benzinga.com - September 5 at 6:30 PM |
| Cannabis Science and Free Spirit Organics Native American Corporation Report Positive Analytical Lab Results From Its 250-Acre, Industrial Hemp Research Project in San Joaquin Sovereign Tribal Free Land MBS, California
finance.yahoo.com - September 5 at 6:30 PM |
| Cannabis Science and Free Spirit Organics Advance ... - Benzinga - Benzinga
www.benzinga.com - August 25 at 6:44 PM |
| Cannabis Science and Free Spirit Organics Advance Comprehensive Economic Development Plans as Part of the 250-Acre Industrial Hemp Project in San Joaquin Sovereign Tribal Free Land MBS, California
finance.yahoo.com - August 25 at 6:44 PM |
| Cannabis Science Launches a Global Consortium and Announces Updates on Its Drug Development Initiatives and ... - Benzinga
www.benzinga.com - August 24 at 5:03 PM |
| Cannabis Science Launches a Global Consortium and Announces Updates on Its Drug Development Initiatives and Research Collaborations
finance.yahoo.com - August 23 at 5:13 PM |
| Breaking News: CBIS/FSAO NAC Harvest Planning Session Held Yesterday Has Accelerated the Completion of the 60-acre Industrial Hemp Project Planted on the 250 acre CBIS/FSO NAC MBS001 Plot Currently Under Harvest
finance.yahoo.com - August 18 at 4:20 AM |
| Breaking News: CBIS/FSAO NAC Harvest Planning Session Held Yesterday Has Accelerated the Completion of the 60 ... - Benzinga
www.benzinga.com - August 17 at 11:18 PM |
| Breaking News: CBIS/FSAO NAC Harvest Planning Session Held Yesterday Has Accelerated the Completion of the 60-acre Industrial Hemp Project Planted on the 250 acre CBIS/FSO NAC MBS001 Plot Currently Under Harvest
finance.yahoo.com - August 17 at 6:17 PM |
| Cannabis Science and Free Spirit Organics Native American Corporation (FSO NAC) Begin Harvesting Approximately 60 Acres of its 250-Acre Industrial Hemp Project on San Joaquin Sovereign Tribal Fee Land MBS, California
finance.yahoo.com - August 16 at 5:28 PM |
| Cannabis Science and Free Spirit Organics Native American Corporation (FSO NAC) Begin Harvesting Approximately 60 Acres of its 250-Acre Industrial Hemp Project on San Joaquin Sovereign Tribal Fee Land MBS, California
finance.yahoo.com - August 16 at 5:28 PM |
| Cannabis Science 2017 Black Tie Gala Event Draws Near as Cannabis Science Completes Major Milestones and ... - Benzinga
www.benzinga.com - August 11 at 5:26 PM |
| Cannabis Science 2017 Black Tie Gala Event Draws Near as Cannabis Science Completes Major Milestones and ... - Benzinga
www.benzinga.com - August 11 at 5:26 PM |
| Cannabis Science 2017 Black Tie Gala Event Draws Near as Cannabis Science Completes Major Milestones and Operational Goals
finance.yahoo.com - August 11 at 5:26 PM |
| Cannabis Science 2017 Black Tie Gala Event Draws Near as Cannabis Science Completes Major Milestones and Operational Goals
finance.yahoo.com - August 11 at 5:26 PM |
| Legal Cannabis and CBD Based Products Continue to Show Robust Growth - PR Newswire (press release)
www.prnewswire.com - August 8 at 9:43 PM |
| Cannabis Science Issues Second Quarter Update Looking Forward to More Quarterly Growth and Progress Reports ... - Benzinga
www.benzinga.com - August 8 at 9:43 PM |
| Cannabis Science Issues Second Quarter Update Looking Forward to More Quarterly Growth and Progress Reports with More New and Exciting Revenue Developments Coming Soon
finance.yahoo.com - August 7 at 5:25 PM |
| Recreational Cannabis Sales to Grow Faster Than Medical ... - PR Newswire (press release)
www.prnewswire.com - August 1 at 2:57 AM |
| Sector Market Growth in Legalization of Cannabis - PR Newswire (press release)
www.prnewswire.com - July 27 at 4:22 PM |
| Cannabis Revenues Climb as Sales Demand Exceeds Legal Marijuana and CBD-based Product Supplies - PR Newswire (press release)
www.prnewswire.com - July 18 at 6:27 PM |
| Cannabis Science, Inc. Finds Large-Scale Manufacturing and Product Distribution Facility in California and Eyes Nevada Property as Nevada Governor Issues Statement of Emergency Due to Potential Shortage of Cannabis
finance.yahoo.com - July 17 at 5:21 PM |
| Cannabis Science Steps Up the Fight Against Opioid Drug Addictions with its Initial Test Batch of Transdermal Patches and Unisex Rectal Suppositories Available Now in Los Angeles Dispensaries, Meeting a Growing Demand from Self-Medicating Patients
finance.yahoo.com - July 8 at 9:32 AM |
| Cannabis Science Releases its 2017 Guidance Report for 2nd Quarter 2017, and Outlines Company's Performance and Growth Opportunities as the Medical Cannabis Industry Expands Dramatically
finance.yahoo.com - July 5 at 5:43 PM |
| Cannabis Science Calls on All MMJ Companies to Recognize and Join the Fight Against Opioid Addiction and Deaths ... - Benzinga
www.benzinga.com - June 28 at 4:58 PM |
| UPDATE - Cannabis Science Releases the Chronic Pain CBIS Transdermal Patches to Meet the Overwhelming ... - Benzinga
www.benzinga.com - June 23 at 4:48 PM |
| Legal Marijuana and CBD-based Products Increasing Demand Continues to Drive Revenue Growth - PR Newswire (press release)
www.prnewswire.com - June 20 at 4:47 PM |
| 2017 Cannabis Market Developments
www.prnewswire.com - May 4 at 4:19 PM |
 | CBIS Subsidiary, Cannabis Science Europe GmbH, Acquires …
uk.finance.yahoo.com - April 7 at 8:51 AM |
 | Cannabis Science's Acquisition Raises More Questions Than Answers
seekingalpha.com - April 7 at 8:51 AM |
| Cannabis Science Senior Executives to Co-Chair...
www.benzinga.com - March 2 at 4:22 PM |
 | Ignore the 'Sessions Effect' and Shun These 2 Over-Hyped Pot Stocks
www.thestreet.com - March 2 at 4:22 PM |
| Cannabis CBD Infused Products Grow in Popularity Along With Newest Medicinal Applications and Uses
www.prnewswire.com - February 28 at 9:15 AM |
| Cannabis Science Announces Update on Proposed DPI Inhalation Device, CBD Infused Pain Patch, and Extends ... - Benzinga
www.benzinga.com - February 25 at 2:22 AM |
| Legal Marijuana Industry Fueling Higher Standard of Production and Preservation for Cannabis Based Products - PR Newswire (press release)
www.prnewswire.com - February 21 at 1:50 PM |
| MarketNewsUpdates.com: Cannabis-Infused Products Boosting Legal Marijuana Industry Revenue Streams
www.prnewswire.com - February 3 at 2:39 AM |
| Marijuana Industry Pushing Toward Federal Acceptance, Expanded Research in 2017
www.prnewswire.com - February 1 at 4:24 PM |
 | Cannabis Science Distributors Sells Out of Initial Test Batch of CBIS Metered Dose Inhalers (MDI), Notes Consumer ... - MarketWatch
www.marketwatch.com - January 26 at 5:01 PM |
 | CANNABIS SCIENCE INC
www.finanznachrichten.de - January 25 at 10:17 PM |
Cannabis Science (CBIS) Chart for Friday, October, 20, 2017
